BPaQM
Phase 3Small molecule
OtsukaBPaQM is one of 28 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Pulmonary Tuberculosis
#DrugCompanyPhaseTrials
1Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Priftin
SanofiApproved
Myambutol
VVA Greater Los Angeles Healthcare System
Approved
Calciferol
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Decadron
AAspen Global Incorporated
Approved
Rayos
RRoxane Laboratories
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Tuberculosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BPaQM. EMBL-EBI & Wellcome Sanger Institute.
- [4]